Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
or

Tscan Therapeutics Inc (TCRX)

Tscan Therapeutics Inc (TCRX)
0.9000 x 1 1.2300 x 2
Pre-market by (Cboe BZX)
1.2400 +0.1100 (+9.73%) 04/11/25 [NASDAQ]
0.9000 x 1 1.2300 x 2
Pre-market 1.2400 unch (unch) 16:00 ET
Quote Overview for Fri, Apr 11th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.1400
Day High
1.2400
Open 1.1700
Previous Close 1.1300 1.1300
Volume 349,300 349,300
Avg Vol 556,990 556,990
Stochastic %K 25.71% 25.71%
Weighted Alpha -82.90 -82.90
5-Day Change +0.1400 (+12.73%) +0.1400 (+12.73%)
52-Week Range 1.0200 - 9.6900 1.0200 - 9.6900
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 70,173
  • Shares Outstanding, K 56,591
  • Annual Sales, $ 2,820 K
  • Annual Income, $ -127,500 K
  • EBIT $ -135 M
  • EBITDA $ -131 M
  • 60-Month Beta 1.09
  • Price/Sales 22.71
  • Price/Cash Flow N/A
  • Price/Book 0.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.28
  • Number of Estimates 3
  • High Estimate -0.25
  • Low Estimate -0.30
  • Prior Year -0.32
  • Growth Rate Est. (year over year) +12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0200 +21.57%
on 04/09/25
Period Open: 1.8200
1.8900 -34.39%
on 03/14/25
-0.5800 (-31.87%)
since 03/11/25
3-Month
1.0200 +21.57%
on 04/09/25
Period Open: 2.7700
2.8500 -56.49%
on 01/14/25
-1.5300 (-55.23%)
since 01/10/25
52-Week
1.0200 +21.57%
on 04/09/25
Period Open: 7.8000
9.6900 -87.20%
on 05/21/24
-6.5600 (-84.10%)
since 04/11/24

Most Recent Stories

More News
TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

TCRX : 1.2400 (+9.73%)
TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access

TCRX : 1.2400 (+9.73%)
TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

TCRX : 1.2400 (+9.73%)
TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference

TCRX : 1.2400 (+9.73%)
TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

TCRX : 1.2400 (+9.73%)
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

TCRX : 1.2400 (+9.73%)
TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank

TCRX : 1.2400 (+9.73%)
2 "Strong Buy"-Rated Biotech Stocks With 303% to 446% Upside Potential

While the upside is appealing, penny stocks carry some risks.

TCRX : 1.2400 (+9.73%)
$SPX : 5,363.36 (+1.81%)
SCPH : 2.32 (+14.85%)
Insider Purchase: 10% owner at $TCRX (TCRX) Buys 31,800 Shares

Capital Management LP Lynx1, a 10% owner of $TCRX ($TCRX), bought 31,800 shares of the company on 12-12-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased...

TCRX : 1.2400 (+9.73%)
TScan Therapeutics Reports Positive Preliminary Results from ALLOHA Phase 1 Trial and Announces Upcoming Virtual KOL Event

TScan Therapeutics reports positive Phase 1 trial results for TCR-T therapies in leukemia, with a KOL event scheduled.Quiver AI SummaryTScan Therapeutics, Inc. reported promising results from the ongoing...

TCRX : 1.2400 (+9.73%)

Business Summary

TScan Therapeutics Inc. is a biopharmaceutical company. It focused on the development of T-cell receptor engineered T cell therapies for the treatment of patients with cancer. The company's lead product pipeline consist TSC-100 and TSC-101. TScan Therapeutics Inc. is based in WALTHAM, Mass.

See More

Key Turning Points

3rd Resistance Point 1.3733
2nd Resistance Point 1.3067
1st Resistance Point 1.2733
Last Price 1.2400
1st Support Level 1.1733
2nd Support Level 1.1067
3rd Support Level 1.0733

See More

52-Week High 9.6900
Fibonacci 61.8% 6.3781
Fibonacci 50% 5.3550
Fibonacci 38.2% 4.3319
Last Price 1.2400
52-Week Low 1.0200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar